Table 1.
Clinicopathological patients' characteristics by AR expression.
| Patients' features | ALL (N = 263) N (%) | AR+ (N = 78) N (%) | AR- (N = 185) N (%) | p | |
|---|---|---|---|---|---|
| Age years, median (Q1-Q3) | 53 (44–66) | 62 (47–70) | 51 (42–62) | 0.002 | |
| Hystotype | Ductal/NOS | 237 (91.2) | 66 (84.6) | 171 (94.0) | |
| Lobular | 7 (2.7) | 5 (6.4) | 2 (1.1) | ||
| Apocrine | 8 (3.1) | 7 (9.0) | 1 (0.5) | ||
| Metaplastic | 5 (1.9) | 0 | 5 (2.7) | ||
| Medullary | 3 (1.2) | 0 | 3 (1.6) | <0.001 | |
| AJCC Stage | I | 83 (31.7) | 24 (30.8) | 59 (32.1) | |
| II | 130 (49.6) | 38 (48.7) | 92 (50.0) | ||
| III | 49 (18.7) | 16 (20.5) | 33 (17.9) | 0.886 | |
| Grade | G1-2 | 29 (11.9) | 16 (21.1) | 13 (7.7) | |
| G3 | 2515 (88.1) | 60 (78.9) | 155 (92.3) | 0.003 | |
| Ki67%, median (Q1-Q3) | 55 (36–70) | 40 (27–60) | 60 (40–70) | <0.001 | |
| TILs%, median (Q1-Q3) | 10 (5–30) | 7 (2–20) | 10 (5–30) | 0.008 | |
| Neoadjuvant CT | Yes | 108 (41.1) | 27 (34.6) | 81 (43.8) | |
| No | 155 (58.9) | 51 (65.4) | 104 (56.2) | 0.167 | |
| Type of neoadjuvant CT | Anthra+tax | 101 (93.5) | 24 (88.9) | 77 (95.1) | |
| Anthra | 1 (0.9) | 0 | 1 (1.2) | ||
| Tax | 6 (5.6) | 3 (11.1) | 3 (3.7) | 0.299 | |
| Adjuvant CT | Yes | 186 (71.3) | 57 (73.1) | 129 (70.5) | |
| No | 75 (28.7) | 21 (26.9) | 54 (29.5) | 0.673 | |
| Type of adjuvant CT | Anthra+tax | 96 (51.6) | 28 (49.1) | 68 (52.7) | |
| Anthra | 37 (19.9) | 14 (24.6) | 23 (17.8) | ||
| Tax | 8 (4.3) | 1 (1.8) | 7 (5.4) | ||
| Other | 45 (24.2) | 14 (24.6) | 31 (24.0) | 0.523 | |
| Radiotherapy | Yes | 165 (67.1) | 48 (64.9) | 117 (68.0) | |
| No | 81 (32.9) | 26 (35.1) | 55 (32.0) | 0.629 | |
N, number, AR, androgen receptor; p, p-value; Q1, first quartile; Q3, third quartile; NOS, not otherwise specified; AJCC, American Joint Committee on Cancer; TILs, tumor infiltrating lymphocytes; CT, chemotherapy; Anthra, anthracycline; Tax, taxane.